JAZZ

Jazz Pharmaceuticals PLC

Add to Watchlist

Advanced Chart

113.330

+2.58(2.330%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

113.420

Open

111.260

VWAP

112.53

Vol

772.67K

Mkt Cap

6.87B

Low

110.260

Amount

86.95M

EV/EBITDA(TTM)

8.09

Total Shares

63.06M

10.41B

EV/OCF(TTM)

7.91

P/S(TTM)

1.67

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Get winning stock picks in minutes

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

941.74M

+4.89%

4.213

+150.74%

1.16B

+6.75%

5.725

-13.25%

1.11B

+5.09%

5.956

-9.89%

Estimates Revision

The market is revising Upward the revenue expectations for Jazz Pharmaceuticals plc (JAZZ) for FY2025, with the revenue forecasts being adjusted by 0.15% over the past three months. During the same period, the stock price has changed by 10.13%.

Revenue Estimates for FY2025

Revise Upward

+0.15%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.6%

In Past 3 Month

Stock Price

Go Up

+10.13%

In Past 3 Month

15 Analyst Rating

54.93% Upside

Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 175.58 USD with a low forecast of 134.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

1 Hold

0 Sell

Strong Buy

54.93% Upside

Current: 113.330

Low

134.00

Averages

175.58

High

230.00

54.93% Upside

Current: 113.330

Low

134.00

Averages

175.58

High

230.00

Truist

Buy

downgrade

$230 -> $200

2025-08-06

Reason

Truist

Price Target

$230 -> $200

2025-08-06

downgrade

Buy

Reason

Truist lowered the firm's price target on Jazz Pharmaceuticals to $200 from $230 and keeps a Buy rating on the shares. The company's inline total revenue was carried by robust momentum in oxybate franchise, off-set by softness in Epidiolex and oncology businesses, the analyst tells investors in a research note. Truist adds however that it is tempering its outlook for oxybate franchise as multiple non-oxybate alternatives to narcolepsy are on the horizon with two NDAs on deck in coming months.

Morgan Stanley

Overweight

downgrade

$166 -> $165

2025-07-22

Reason

Morgan Stanley

Price Target

$166 -> $165

2025-07-22

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on Jazz Pharmaceuticals to $165 from $166 and keeps an Overweight rating on the shares. The firm, which sees several factors that should lead to a stronger Q2 after a "meaningful miss" on revenue in Q1, sees Jazz as likely entering a key inflection point in the second half with major clinical catalysts, the analyst tells investors in a preview.

Deutsche Bank

David Hoang

Buy

initiated

$152

2025-07-15

Reason

Deutsche Bank

David Hoang

Price Target

$152

2025-07-15

initiated

Buy

Reason

Deutsche Bank analyst David Hoang initiated coverage of Jazz Pharmaceuticals with a Buy rating and $152 price target.

Deutsche Bank

David Hoang

Buy

initiated

$152

2025-07-15

Reason

Deutsche Bank

David Hoang

Price Target

$152

2025-07-15

initiated

Buy

Reason

As previously reported, Deutsche Bank analyst David Hoang initiated coverage of Jazz Pharmaceuticals with a Buy rating and $152 price target. The firm attributes the recent pullback to macro developments, including President Trump's threat of pharma tariffs and Most Favored Nation pricing, given that Jazz is an Irish-domiciled company. However, Deutsche believes the stock's valuation discount is not warranted. Jazz is entering a period of value creation through the second half of 2027, with expansion of its oncology business and "resilience" of the neuroscience business, which should translate to growth, the analyst tells investors in a research note.

Needham

Ami Fadia

Strong Buy

Reiterates

$210

2025-04-10

Reason

Needham

Ami Fadia

Price Target

$210

2025-04-10

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Oren Livnat

Strong Buy

Maintains

$200 → $217

2025-03-10

Reason

HC Wainwright & Co.

Oren Livnat

Price Target

$200 → $217

2025-03-10

Maintains

Strong Buy

Reason

See All Ratings

Get winning stock picks in minutes

Valuation Metrics

The current forward P/E ratio for Jazz Pharmaceuticals PLC (JAZZ.O) is 5.20, compared to its 5-year average forward P/E of 8.24. For a more detailed relative valuation and DCF analysis to assess Jazz Pharmaceuticals PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

8.24

Current PE

5.20

Overvalued PE

10.63

Undervalued PE

5.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

7.54

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

8.90

Undervalued EV/EBITDA

6.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.30

Current PS

0.00

Overvalued PS

2.83

Undervalued PS

1.77

Financials

Annual

Quarterly

FY2025Q2

YoY :

+2.14%

1.05B

Total Revenue

FY2025Q2

YoY :

+9.79%

218.97M

Operating Profit

FY2025Q2

YoY :

-526.14%

-718.38M

Net Income after Tax

FY2025Q2

YoY :

-571.49%

-11.74

EPS - Diluted

FY2025Q2

YoY :

-76.60%

75.89M

Free Cash Flow

FY2025Q2

YoY :

-0.97%

73.38

Gross Profit Margin - %

FY2025Q2

YoY :

+16.69%

30.34

FCF Margin - %

FY2025Q2

YoY :

-517.44%

-68.71

Net Margin - %

FY2025Q2

YoY :

-100.00%

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

329.8K

USD

3-6

Months

2.8M

USD

6-9

Months

2.0M

USD

0-12

Months

720.2K

USD

Bought

0-3

0.0

USD

Months

3-6

10.0M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.0K

Volume

6-9

Months

393.0K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

170.0K

Volume

Months

6-9

1.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

329.8K

USD

3-6

Months

2.8M

USD

6-9

Months

2.0M

USD

0-12

Months

720.2K

USD

Bought

0-3

0.0

USD

Months

3-6

10.0M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

JAZZ News & Events

Events Timeline

2025-08-05 (ET)

2025-08-05

16:20:53

Jazz narrows FY25 EPS view $4.80-$5.60 from $4.00-$5.60

2025-08-05

16:18:31

Jazz Pharmaceuticals reports Q2 adjusted EPS ($8.25), consensus ($6.25)

2025-07-10 (ET)

2025-07-10

07:34:31

Jazz Pharmaceuticals appoints Renee Gala as President, CEO

News

9.0

08-06PRnewswire

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

6.0

08-05TipRanks

3 “Strong Buy” Growth Stocks to Buy Now, 8/5/2025, According to Analysts

9.5

08-05NASDAQ.COM

Jazz Pharmaceuticals Plc Q2 Earnings Summary